Brain Navi Biotechnology Co., Ltd.: TFDA Approves the First Autonomous Neurosurgical Navigation Robot, NaoTrac, from Brain Navi Biotechnology

HSINCHU, Aug. 8, 2022 /PRNewswire/ -- NaoTrac, the CE-certified neurosurgical navigation robot, achieved approval from Taiwan's Food and Drug Administration (TFDA) in July 2022, and is planned

Related Keywords

Taiwan ,Hualien ,Hualian Xian ,Washington ,United States ,San Francisco ,California ,Taiwanese ,Kostenloser Wertpapierhandel ,Acta Neurochirurgica ,Prnewswire Naotrac ,Surface Mapping Technology ,Hualien Tzu Chi Medical Center ,Registration Technology ,Drug Administration ,External Ventricular Drain ,Surface Mapping Auto Registration Technology ,Taiwan Expo United States ,Navi Biotechnology ,Brain ,Avi ,Biotechnology ,Fda ,Pproves ,First ,Utonomous ,Neurosurgical ,Navigation ,Robot ,Aotrac ,Rom ,